Anthem likely to leave ACA markets for 2018

Financial analysts are predicting Anthem, one of the nation’s largest health insurers, will be following other national companies in leaving the Affordable Care Act (ACA)’s exchanges in 2018.

Anthem is “is leaning toward exiting a high percentage of the 144 rating regions in which it currently participates,” according to a research note from Jefferies analysts David Windley and David Styblo obtained by Bloomberg.

The insurer sold plans under the Blue Cross Blue Shield brand in 14 states for 2017. Anthem CEO Joseph Swedish had already threatened to scale back for 2018, and had notably been one of the few voices in healthcare to support President Donald Trump’s now-scrapped ACA replacement plan, the American Health Care Act (AHCA).

Without changes to stabilize the market, Swedish said Anthem would have to “significantly extract” itself from exchange participation after losing a total of $374 million on the individual market in 2016. The same Bloomberg report mentions, however, that Anthem expects to turn a “modest” profit on its exchange business this year.

No help from the Trump administration appears to be forthcoming, as the president himself has predicted the ACA will “explode” in the coming months. HHS Secretary Tom Price was noncommittal about taking planned regulatory actions at a congressional hearing on March 29, though he did vow to “uphold the law” of the ACA.

According to an analysis from Axios, an Anthem departure could affect up to 815,000 customers. Around 255,000 enrollees in Colorado, Kentucky, Missouri and Ohio would be at risk of having no available insurers on the exchanges, and the ACA doesn’t have a provision to guarantee coverage if no insurer elects to participate in some areas.

If Anthem follows through on the exit rumors, it would join several other major insurers who have left the ACA marketplace. UnitedHealth exited almost all markets for 2017, while Aetna and Humana planned to do the same next year after their proposed merger was blocked by the federal government in court.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.